21 Jun Trial of Antibody Immunotherapy in Parkinson’s Disease
MedicalResearch.com Interview with:
Joseph Jankovic, MD
Professor of Neurology
Distinguished Chair in Movement Disorders
Director, Parkinson’s Disease Center
and Movement Disorders Clinic
Department of Neurology
Baylor College of Medicine
Baylor St. Luke’s Medical Center at the McNair Campus
Houston, TX 77030-4202
MedicalResearch.com: What should readers take away from your study?
- First demonstration of an anti-α-synuclein antibody immunotherapy in patients with Parkinson’s Disease.
- Robust target engagement led to mean reduction of up to 97% in serum free α-synuclein levels.
- Central Nervous System penetration is supported by a dose-dependent increase in PRX002/RG7935 levels in Cerebral Spinal Fluid.
- All dose levels of PRX002/RG7935 had acceptable safety and tolerability profiles, meeting the primary objective of this study
- Data support ongoing PASADENA Phase 2 clinical study of PRX002/RG7935 (NCT03100149)
Jankovic J, Goodman I, Safirstein B, et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson DiseaseA Randomized Clinical Trial. JAMA Neurol. Published online June 18, 2018. doi:10.1001/jamaneurol.2018.1487
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.